News Research news

SLEIPNIR, the new multi-arm clinical trial platform for Parkinson’s treatments

Cure Parkinson’s is excited to announce £1 million in funding for SLEIPNIR – an upcoming multi-arm clinical trial platform in Norway. One of the ongoing challenges for Parkinson’s research is determining whether treatments are reaching the brain and if they are having their intended effect…


New findings from the TransEuro cell replacement trial are now published

Parkinson’s is characterised by the progressive loss of dopamine nerve cells (neurons) in an area of the brain associated with movement. Therefore, researchers have been investigating whether cell transplantations have potential to replace the neurons lost, to slow or reverse progression of the condition. What…


News Research news

Cure Parkinson’s welcomes a new research committee chair

Every research project that Cure Parkinson’s funds must be recommended by our research committee – an independent board of leading Parkinson’s researchers, clinicians, people with Parkinson’s, patient advocates and experts in intellectual property and regulatory affairs, who meet four times a year to evaluate new…


News Research news

The ASPro-PD trial is now underway

We are excited to announce that the first clinical centre for the ASPro-PD trial opened in February of this year, with the first participant enrolled earlier this month. This follows a delay to the start date due to drug reformulation issues which have now been…


Neurotrophic factors for Parkinson’s: insights from a previous workshop

In 2023, Cure Parkinson’s hosted a workshop where leading experts reviewed the potential of neurotrophic factors as a treatment for Parkinson’s disease. A commentary paper summarising the key outcomes was recently published in the Journal of Parkinson’s Disease. What are neurotrophic factors? Neurotrophic factors, or…